

10/511924  
Rec'd PCT/PTO 18 OCT 2004  
PCT/EP 0 37 0 42 31

REC'D 27 JUN 2003

WIPO PCT

PA 1017614

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

May 30, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 10/125,508

FILING DATE: April 19, 2002

PRIORITY DOCUMENT  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

EPO - DG 1

16. 06. 2003

(71)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*H. Phillips*  
H. PHILLIPS  
Certifying Officer

1131 U.S. PTO

Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0851-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 272/142  
First Inventor John W. Fong  
Title PHOTOCURABLE COMPOSITIONS CONTAINING REACTIVE POLYSILOXANE PARTICLES  
Express Mail Label No.

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit on original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification (Total Pages 26)  
(prepared arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure

4. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets ☐]

5. Oath or Declaration [Total Pages ☐]

- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63 (d))  
(for continuation/divisional with Box 18 completed)

1. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.63(b).

8. ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    1. ☐ CD-ROM or CD-R (2 copies); or
    11. ☐ paper
  - c. ☐ Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9. ☒ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Claims
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other: .....

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

Prior application information:

Examiner

of prior application No. \_\_\_\_\_

Group Art Unit

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

22249

or ☐ Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

Fax

Name (Print/Type)

Rouget F. Henschel

Registration No. (Attorney/Agent)

39,221

Signature

Date

19-APR-02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.  
DC-10324.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

# FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

## Complete if Known

Application Number	
Filing Date	
First Named Inventor	John W. Fong
Examiner Name	
Group Art Unit	
Attorney Docket No.	272/142

TOTAL AMOUNT OF PAYMENT (\$) 740.00

## METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 12-2475

Deposit Account Name: Lyon & Lyon LLP

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

## FEE CALCULATION

1. BASIC FILING FEE				
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	
101 740	201 370	Utility filing fee	740.00	
106 330	206 165	Design filing fee		
107 510	207 255	Plant filing fee		
108 740	208 370	Reissue filing fee		
114 160	214 80	Provisional filing fee		
SUBTOTAL (1)			(\$)	740.00

2. EXTRA CLAIM FEES				
Total Claims	Extra Claims	Fee from below	Fee Paid	
20	-20** = 0	X	0.00	
3	-3** = 0	X	0.00	
Multiple Dependent			0.00	0.00

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	
103 18	203 9	Claims in excess of 20	
102 84	202 42	Independent claims in excess of 3	
104 280	204 140	Multiple dependent claim, if not paid	
109 84	209 42	** Reissue independent claims over original patent	
110 18	210 9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)			(\$)

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for ex parte reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
118 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	
118 1,440	218 720	Extension for reply within fourth month	
128 1,860	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	
120 320	220 160	Filing a brief in support of an appeal	
121 280	221 140	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 460	243 230	Design issue fee	
144 620	244 310	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(q)	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	
178 740	278 370	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	
Other fee (specify)			0.00

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY		Complete (if applicable)	
Name (Print/Type)	Rouget F. Henschel	Registration No.	39,221
Signature		Telephone	202-974-6018
		Date	19-APR-02

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**Title: Photocurable Compositions Containing Reactive Polysiloxane Particles**

**Inventors: John W. Fong, David L. Johnson**

## **BACKGROUND OF THE INVENTION**

### **Field of the Invention**

[0001] The invention relates to photocurable compositions, more particularly to photocurable compositions for stereolithography.

### **Related Art**

[0002] U.S. Patent No. 5,002,854 to Fan et al. discloses a photohardenable composition for stereolithography containing filler particles that are core shell polymers. The core is a crosslinked multifunctional ethylenically unsaturated monomer; the shell is based on a monofunctional ethylenically unsaturated monomer. The particles are non-reactive and do not chemically bond to the polymer matrix formed on curing the composition.

[0003] U.S. Patent No. 5,461,088 to Wolf et al. discloses a stereolithography formulation containing a polysiloxane block copolymer that is added to the formulation as an oil or crystals. The block copolymer is not a core-shell polymer and contains no reactive epoxy groups or ethylenically unsaturated groups. U.S. Patent No. 5,463,084 to Crivello et al. discloses a photocurable composition containing silicone oxetane monomers that are liquid. U.S. Patent No. 5,639,413 to Crivello discloses a photocurable composition containing a cyclohexylepoxy siloxane monomer that is liquid.

[0004] 3-D objects made by stereolithography are generally clear or slightly hazy, and tend to have rough surfaces. Opaque white objects with smooth surfaces are desirable as similar to plastic objects made by non-stereolithography processes. Smooth sidewalls are especially useful when using an object prepared from

DC-10341.1

stereolithography as a model to prepare a mold. There is therefore a need for alternative photocurable compositions for stereolithography to allow for variation in color, opacity, and surface properties. In particular, there is a need for stereolithography compositions that form opaque white objects with improved surface properties.

### SUMMARY OF THE INVENTION

[0005] The invention provides a photocurable composition, including (a) a cationically curable monomer; (b) a radically curable monomer; (c) reactive particles comprising a crosslinked polysiloxane core and a shell of reactive groups on an outer surface of the core, wherein the reactive groups comprise epoxy groups, ethylenically unsaturated groups, or hydroxy groups; (d) a radical photoinitiator; and (e) a cationic photoinitiator.

[0006] The invention also provides a method of making a 3-D object from such a composition by forming a first layer of the photocurable composition; exposing the first layer to actinic radiation sufficient to harden the first layer; forming a second layer of the photocurable composition above the hardened first layer; exposing the second layer to actinic radiation sufficient to harden the second layer; and repeating the previous two steps as needed to form a 3-D object.

### DETAILED DESCRIPTION OF THE INVENTION

[0007] "Stereolithography" is a process that produces solid objects from computer-aided design ("CAD") data. CAD data of an object is first generated and then is sliced into thin cross sections. A computer controls a laser beam that traces the pattern of a slice through a liquid plastic, solidifying a thin layer of the plastic corresponding to the slice. The solidified layer is recoated with liquid plastic and the laser beam traces another slice to harden another layer of plastic on top of the previous one. The process continues layer by layer to complete the part. A desired

part may be built in a matter of hours. This process is described in U.S. Patent No. 5,476,748 to Steinmann et al., U.S. Patent Publication No. 2001/0046642 to Johnson et al., and by Jacobs in "Rapid Prototyping & Manufacturing" (Society of Manufacturing Engineers, 1992), the entire contents of which documents are incorporated herein by reference.

[0008] "3-D object" means a three-dimensional object made from at least two layers of a cured resin composition.

[0010] "Polymerization" is a chemical reaction linking monomers to form larger molecules. The resulting polymers have units that correspond to the monomers.

[0011] A "monomer" is a compound that is capable of polymerizing with other monomers to form a polymer chain or matrix. The term "monomer" refers to compounds with one or more reactive groups and includes oligomers that are, e.g., dimers or trimers formed from two or three monomer units, respectively.

[0012] "Crosslinked" means a polymer that contains bonds between atoms of two or more different polymer chains. The result is a matrix that develops rigidity because the polymer chains are bonded together and can not flow freely. Crosslinked polymers generally result from polymerizing monomers that have more than one reactive site, i.e., the monomers are polyfunctional.

[0013] "Curing" means to polymerize a mixture including one or more monomers and one or more initiators. "Hardening" may be synonymous with curing and emphasizes that when polymerized, liquid monomer mixtures tend to become solid.

[0014] "Photocurable composition" means a composition that may be cured or hardened by a polymerization reaction that is initiated by actinic radiation.

[0015] "Actinic radiation" is light energy at a wavelength that allows a given chemical compound to absorb the light energy and form a reactive species. For

stereolithography, typically a laser beam or a flood lamp generates the actinic radiation.

[0016] "Cationically curable" means a monomer that can polymerize by cationic polymerization, a mechanism that involves cations, i.e., chemical species that are positively charged.

[0017] "Radically curable" means a monomer that can polymerize by radical polymerization, a mechanism that involves radicals, i.e., chemical species with an unpaired valence electron.

[0018] "Photoinitiator" is a compound that absorbs actinic radiation to form a reactive species that initiates a chemical reaction such as polymerization.

[0019] A "cationic photoinitiator" is a photoinitiator that generates cations when exposed to actinic radiation and thereby initiates cationic polymerization.

[0020] A "radical photoinitiator" is a photoinitiator that generates radicals when exposed to actinic radiation and thereby initiates radical polymerization.

[0021] "(Meth)acrylate" refers to an acrylate, methacrylate, or a combination thereof.

[0022] "Hybrid composition" means a photocurable composition with at least one radically curable component and at least one cationically curable component.

#### A. Cationically Curable Monomer

[0023] Examples of cationically curable monomers are disclosed in, e.g., U.S. Patent No. 5,476,748 and U.S. Patent Publication No. 2001/0046642 A1, both incorporated herein by reference.

[0024] The photocurable composition preferably contains from 15 to 80 % by weight of cationically curable monomer, more preferably from 50 to 75 % by weight.

[0025] The cationically curable monomer may include one or more epoxide compounds in which the epoxide groups form part of an alicyclic or heterocyclic

ring system. The alicyclic epoxide preferably includes at least one alicyclic polyepoxide having at least two epoxy groups per molecule. Preferably, the alicyclic polyepoxide is in a relatively pure form in terms of oligomer (e.g., dimer, trimer, etc.) content. Preferably, the alicyclic polyepoxide has a monomer purity of over about 90 %, more preferably over about 94 %, even more preferably 98 % or higher. Ideally, dimers or trimers or higher oligomers are substantially eliminated. Preferably, the alicyclic polyepoxide has an epoxy equivalent weight from 80 and 330, more preferably from 90 and 300, even more preferably from 100 and 280.

[0026] Examples of alicyclic polyepoxides include bis(2,3-epoxycyclopentyl) ether, 2,3-epoxycyclopentyl glycidyl ether, 1,2-bis(2,3-epoxycyclopentyl)oxy)ethane, bis(4-hydroxycyclohexyl)methane diglycidyl ether, 2,2-bis(4-hydroxycyclohexyl)propane diglycidyl ether, 3,4-epoxycyclohexylmethyl 3,4-epoxycyclohexanecarboxylate, 3,4-epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanecarboxylate, di(3,4-epoxycyclohexylmethyl) hexanedioate, di(3,4-epoxy-6-methylcyclohexylmethyl) hexanedioate, ethylenebis(3,4-epoxycyclohexanecarboxylate, ethanediol di(3,4-epoxycyclohexylmethyl) ether, vinylcyclohexene dioxide, dicyclopentadiene diepoxide or 2-(3,4-epoxycyclohexyl-5,5-spiro-3,4-epoxy)cyclohexane-1,3-dioxane.

[0027] 3,4-epoxycyclohexylmethyl 3',4'-epoxycyclohexanecarboxylate having an epoxy equivalent weight from 130 and 145 with varying degrees of monomer purity are commercially available. Araldite CY179 of Ciba Speciality Chemicals has monomer purity of about 90 %. UVR6105 of DOW Corp. contains a smaller percentage of oligomers and thus has higher monomer purity than Araldite CY 179. Preferred is Uvacure 1500 of UCB Radcure Corp., which has monomer purity of about 98.5 %.



[0028] The photocurable composition preferably contains from 5 to 80 % by weight, more preferably from 10 and 75 % by weight, even more preferably from 15 to 70 % by weight of alicyclic polyepoxide.

[0029] The component (a) may include a monomer with at least one epoxycyclohexyl group that is bonded directly or indirectly to a group containing at least one silicon atom. These monomers may be linear, branched, or cyclic in structure. Examples are disclosed in U.S. Pat. No. 5,639,413, which is incorporated herein by reference.

[0030] The photocurable composition preferably includes one or more cationically curable compounds that are polyglycidyl ethers, poly( $\beta$ -methylglycidyl) ethers, polyglycidyl esters, poly( $\beta$ -methylglycidyl) esters, poly(N-glycidyl) compounds, and poly(S-glycidyl) compounds. Cationically curable oxetanes are disclosed in U.S. Pat. No. 5,463,084, incorporated herein by reference.

[0031] Polyglycidyl ethers can be obtained by reacting a compound having at least two free alcoholic hydroxyl groups and/or phenolic hydroxyl groups with a suitably substituted epichlorohydrin under alkaline conditions or in the presence of an acidic catalyst followed by alkali treatment. Ethers of this type may be derived, for example, from acyclic alcohols, such as ethylene glycol, diethylene glycol and higher poly(oxyethylene) glycols, propane-1,2-diol, or poly(oxypropylene) glycols, propane-1,3-diol, butane-1,4-diol, poly(oxytetramethylene) glycols, pentane-1,5-diol, hexane-1,6-diol, hexane-2,4,6-triol, glycerol, 1,1,1-trimethylolpropane, bistrimethylolpropane, pentaerythritol, sorbitol, and from polyepichlorohydrins. Suitable glycidyl ethers can also be obtained from cycloaliphatic alcohols such as 1,3- or 1,4-dihydroxycyclohexane, bis(4-hydroxycyclohexyl)methane, 2,2-bis(4-hydroxycyclohexyl)propane or 1,1-bis(hydroxymethyl)cyclohex-3-ene, or aromatic alcohols such as N,N-bis(2-hydroxyethyl)aniline or p,p'-bis(2-hydroxyethylamino)diphenylmethane.

[0032] Examples of preferred polyglycidyl ethers include trimethylolpropane triglycidyl ether, triglycidyl ether of polypropoxylated glycerol, and diglycidyl ether of 1,4-cyclohexanedimethanol.

[0033] The following are examples of commercially available cationically curable monomers: Uvacure 1500, Uvacure 1501, Uvacure 1502 (1501 and 1502 have been discontinued by UCB), Uvacure 1530, Uvacure 1531, Uvacure 1532, Uvacure 1533, Uvacure 1534, Uvacure 1561, Uvacure 1562, all commercial products of UCB Radcure Corp., Smyrna, GA; UVR-6100, UVR-6105, UVR-6110, UVR-6128, UVR-6200, UVR-6216 of DOW Corp.; the Araldite GY series that is Bisphenol A epoxy liquid resins, the Araldite CT and GT series that is Bisphenol A epoxy solid resins, the Araldite GY and PY series that is Bisphenol F epoxy liquids, the cycloaliphatic epoxides Araldite CY 179 and PY 284, the Araldite DY and RD reactive diluents series, the Araldite ECN series of epoxy cresol novolacs, the Araldite EPN series of epoxy phenol novolacs, all commercial products of Ciba Specialty Chemicals Corp., the Heloxy 44, Heloxy 48, Heloxy 84, Heloxy 107, and others in the Heloxy product line, the EPON product line, all of Resolution Performance Products (Houston, Texas), the DER series of flexible aliphatic and Bisphenol A liquid or solid epoxy resins, the DEN series of epoxy novolac resins, all commercial products of Dow Corp.; Celoxide 2021, Celoxide 2021P, Celoxide 2081, Celoxide 2083, Celoxide 2085, Celoxide 2000, Celoxide 3000, Glycidole, AOEX-24, Cyclomer A200, Cyclomer M-100, Epolead GT-300, Epolead GT-302, Epolead GT-400, Epolead 401, Epolead 403, (Daicel Chemical Industries Co., Ltd.), Epicoat 828, Epicoat 812, Epicoat 872, Epicoat CT 508 (Yuka Shell Co., Ltd.), KRM-2100, KRM-2110, KRM-2199, KRM-2400, KRM-2410, KRM-2408, KRM-2490, KRM-2200, KRM-2720, KRM-2750 (Asahi Denka Kogyo Co., Ltd.).

[0034] The cationically curable monomer may include compounds containing vinyl ether groups. Preferred examples are aliphatic polyalkoxy di(poly)vinylethers, polyalkylene di(poly)vinylethers, and hydroxy-functionalized

mono(poly)vinylethers. More preferred vinylethers are those having aromatic or alicyclic moieties in their molecules. Preferably, the vinylether component is from 0.5 to 20 % by weight of the photocurable composition. More preferably the vinylether component is from 2 to 17 % by weight. Even more preferably, the vinyl ether component is from 3 to 14 % by weight.

[0035] Examples of vinyl ethers include ethyl vinylether, n-propyl vinylether, isopropyl vinylether, n-butyl vinylether, isobutyl vinylether, octadecyl vinylether, cyclohexyl vinylether, butanediol divinylether, cyclohexanedimethanol divinylether, diethyleneglycol divinylether, triethyleneglycol divinylether, tert-butyl vinylether, tert-amyl vinylether, ethylhexyl vinylether, dodecyl vinylether, ethyleneglycol divinylether, ethyleneglycolbutyl vinylether, hexanediol divinylether, triethyleneglycol methylvinylether, tetraethyleneglycol divinylether, trimethylolpropane trivinylether, aminopropyl vinylether, diethylaminoethyl vinylether, ethylene glycol divinyl ether, polyalkylene glycol divinyl ether, alkyl vinyl ether and 3,4-dihydropyran-2-methyl 3,4-dihydropyran-2-carboxylate. Examples of commercial vinyl ethers include the Pluriol-E200 divinyl ether (PEG200-DVE), poly-THF290 divinylether (PTHF290-DVE) and polyethyleneglycol-520 methyl vinylether (MPEG500-VE) all of BASF Corp.

[0036] Examples of hydroxy-functionalized mono(poly)vinylethers include polyalkyleneglycol monovinylethers, polyalkylene alcohol-terminated polyvinylethers, butanediol monovinylether, cyclohexanedimethanol monovinylether, ethyleneglycol monovinylether, hexanediol monovinylether, and diethyleneglycol monovinylether.

[0037] Further examples of vinyl ethers are disclosed in U.S. Patent No. 5,506,087, incorporated herein by reference.

[0038] Examples of commercial vinyl ethers include Vectomer 4010 (HBVE isophthalate), Vectomer 4020 (pentanedioic acid, bis[[4-[(ethenyloxy)methyl]cyclohexyl]methyl] ester), Vectomer 4051 (CHMVE

terephthalate), Vectomer 4060 (vinyl ether terminated aliphatic ester monomer: HBVE adipate), and Vectomer 5015 (tris(4-vinyloxybutyl)trimellitate), all of Morflex, Inc., Greensboro, NC. Preferred vinyl ethers are Vectomer 4010 and Vectomer 5015.

[0039] The photocurable composition of the invention may include mixtures of the cationically curable compounds described above.

#### B. Radically Curable Monomer

[0040] The radically curable monomer (b) of the invention is preferably ethylenically unsaturated. More preferably, the monomer is a (meth)acrylate. The monomer may include at least one poly(meth)acrylate, e.g., a di-, tri-, tetra- or pentafunctional monomeric or oligomeric aliphatic, cycloaliphatic, or aromatic (meth)acrylate. The poly(meth)acrylate preferably has a molecular weight of from 200 to 500.

[0041] Examples of di(meth)acrylates include di(meth)acrylates of cycloaliphatic or aromatic diols such as 1,4-dihydroxymethylcyclohexane, 2,2-bis(4-hydroxy-cyclohexyl)propane, bis(4-hydroxycyclohexyl)methane, hydroquinone, 4,4'-dihydroxybiphenyl, Bisphenol A, Bisphenol F, bisphenol S, ethoxylated or propoxylated Bisphenol A, ethoxylated or propoxylated Bisphenol F, and ethoxylated or propoxylated bisphenol S. Di(meth)acrylates of this kind are known and some are commercially available, e.g., Ebecryl 3700 (UCB Chemicals).

[0042] Alternatively, the di(meth)acrylate may be acyclic aliphatic, rather than cycloaliphatic or aromatic.

[0043] Preferably, the poly(meth)acrylate includes a tri(meth)acrylate or higher. Preferred compositions are those in which the free radically curable component contains a tri(meth)acrylate or a penta(meth)acrylate. Examples are the tri(meth)acrylates of hexane-2,4,6-triol, glycerol, 1,1,1-trimethylolpropane, ethoxylated or propoxylated glycerol, and ethoxylated or propoxylated 1,1,1-

trimethylolpropane. Other examples are the hydroxyl-containing tri(meth)acrylates obtained by reacting triepoxide compounds (e.g., the triglycidyl ethers of the triols listed above) with (meth)acrylic acid. Other examples are pentaerythritol tetraacrylate, bistrimethylolpropane tetraacrylate, pentaerythritol monohydroxytri(meth)acrylate, or dipentaerythritol monohydroxypenta(meth)acrylate.

[0044] The poly(meth)acrylate may include polyfunctional urethane (meth)acrylates. Urethane (meth)acrylates can be prepared by, e.g., reacting a hydroxyl-terminated polyurethane with acrylic acid or methacrylic acid, or by reacting an isocyanate-terminated prepolymer with hydroxyalkyl (meth)acrylates to give the urethane (meth)acrylate.

[0045] Examples of suitable aromatic tri(meth)acrylates are the reaction products of triglycidyl ethers of trihydric phenols and phenol or cresol novolaks containing three hydroxyl groups, with (meth)acrylic acid.

[0046] The following are examples of commercial poly(meth)acrylates: SR® 295, SR® 350, SR® 351, SR® 367, SR® 368, SR® 399, SR® 444, SR® 454, and SR® 9041 (SARTOMER Company).

[0047] SR® 368 is an example of an isocyanurate triacrylate, which is preferably included in the photocurable composition with a smaller amount of a monohydroxypentaacrylate such as SR® 399 to avoid producing tacky sidewalls in the 3-D object.

[0048] Additional examples of commercially available acrylates include KAYARAD R-526, HDDA, NPGDA, TPGDA, MANDA, R-551, R-712, R-604, R-684, PET-30, GPO-303, TMPTA, THE-330, DPHA-2H, DPHA-2C, DPHA-21, D-310, D-330, DPCA-20, DPCA-30, DPCA-60, DPCA-120, DN-0075, DN-2475, T-1420, T-2020, T-2040, TPA-320, TPA-330, RP-1040, R-011, R-300, R-205 (Nippon Kayaku Co., Ltd.), Aronix M-210, M-220, M-233, M-240, M-215, M-305, M-309, M-310, M-315, M-325, M-400, M-6200, M-6400 (Toagosei Chemical

Industry Co, Ltd.), Light acrylate BP-4EA, BP-4PA, BP-2EA, BP-2PA, DCP-A (Kyoeisha Chemical Industry Co., Ltd.), New Frontier BPE-4, TEICA, BR-42M, GX-8345 (Daichi Kogyo Seiyaku Co., Ltd.), ASF-400 (Nippon Steel Chemical Co.), Ripoxy SP-1506, SP-1507, SP-1509, VR-77, SP-4010, SP-4060 (Showa Highpolymer Co., Ltd.), NK Ester A-BPE-4 (Shin-Nakamura Chemical Industry Co., Ltd.), SA-1002 (Mitsubishi Chemical Co., Ltd.), Viscoat-195, Viscoat-230, Viscoat-260, Viscoat-310, Viscoat-214HP, Viscoat-295, Viscoat-300, Viscoat-360, Viscoat-GPT, Viscoat-400, Viscoat-700, Viscoat-540, Viscoat-3000, Viscoat-3700 (Osaka Organic Chemical Industry Co., Ltd.).

[0049] Preferably, the radically curable monomer includes a compound having at least one terminal and/or at least one pendant (i.e., internal) unsaturated group and at least one terminal and/or at least one pendant hydroxyl group. The composition may contain more than one such compound. Examples of such compounds include hydroxy mono(meth)acrylates, hydroxy poly(meth)acrylates, hydroxy monovinylethers, and hydroxy polyvinylethers. Commercially available examples include dipentaerythritol pentaacrylate (SR® 399), pentaerythritol triacrylate (SR® 444), and bisphenol A diglycidyl ether diacrylate (Ebecryl 3700).

[0050] The photocurable composition preferably contains up to 60 %, more preferably from 5 to 20 %, even more preferably from 9 to 15 % of radically curable monomer(s).

[0051] In one embodiment, the photocurable composition contains up to 40 % by weight, more preferably from 5 to 20 % by weight, of a cycloaliphatic or aromatic di(meth)acrylate and up to 15 % by weight, preferably up to 10 % by weight of a poly(meth)acrylate with 3 or more (meth)acrylate groups. The ratio of diacrylate to poly(meth)acrylate with 3 or more (meth)acrylate groups may vary, but preferably the latter is no more than 50 % of total (meth)acrylates.

[0052] In another embodiment, the photocurable composition may contain much smaller relative amounts of di(meth)acrylate, and may even contain

exclusively poly(meth)acrylates with 3 or more (meth)acrylate groups as radically curable monomer (b) with no or substantially no di(meth)acrylate.

[0053] The photocurable composition of the invention may include mixtures of the radically curable compounds described above.

### C. Reactive Particles

[0054] The reactive particles have a core containing a crosslinked polysiloxane and a shell containing reactive groups.

[0055] The reactive particles may be made by the method disclosed in U.S. Patent No. 4,853,434 to Block, incorporated in its entirety herein by reference. Block discloses reactive particles that are useful in producing fiber-reinforced plastics, structural adhesives, laminated plastics, and annealing lacquers.

[0056] The core is a crosslinked polyorganosiloxane rubber that may include dialkylsiloxane repeating units, where "alkyl" is C1-C6 alkyl. The core preferably includes dimethylsiloxane repeating units.

[0057] The reactive groups preferably include epoxy groups, ethylenically unsaturated groups, and/or hydroxy groups. For example, the reactive groups may include oxirane, glycidyl, vinyl ester, vinyl ether, or acrylate groups, or combinations thereof.

[0058] The reactive particles react with the polymer matrix that forms when the photocurable composition is polymerized by forming one or more chemical bonds to the polymer matrix via the reactive groups. Preferably, the reactive groups react substantially completely on curing the photocurable composition.

[0059] The amount of reactive particles in the photocurable composition may be varied as needed depending on the particular components (a) and (b) in a given photocurable composition. At high concentrations of reactive particles the photocurable composition may become too viscous and bubble formation may be a

problem. Preferably the photocurable composition contains from 1 to 50 % by weight of the reactive particles, more preferably from 5 to 15 % by weight.

[0060] The reactive particles preferably have an average particle diameter of 0.01 to 50  $\mu\text{m}$ , more preferably 0.1 to 5  $\mu\text{m}$ .

[0061] Preferred reactive particles that are available commercially are Albidur EP 2240, Albidur VE 3320, and Albidur EP 5340 (Hanse Chemie, Germany). Preferably, the reactive particles are added to the photocurable composition as a mixture of the reactive particles and a reactive liquid medium containing, e.g., epoxy or ethylenically unsaturated groups. For example, in Albidur EP 2240, the reactive organosiloxane particles are dispersed in bisphenol A glycidyl ether, in bisphenol A vinyl ester for Albidur VE 3320, and in cycloaliphatic epoxide for Albidur EP 5340.

[0062] Commercial dispersions of reactive particles may be heated at from 50 to 60 °C to reduce viscosity, preferably without stirring. Stirring while heating may cause instability in the reactive particles. The commercially available reactive particle dispersions are preferably used within the manufacturer's listed shelf life; otherwise the solids may coagulate and settle out of solution over time.

[0063] Compatibility of the reactive particles and the commercially available dispersions thereof with components (a) and (b) will vary depending on their relative polarities. This must be taken into account in preparing formulations that are suitable for stereolithography.

#### D. Photoinitiators

[0064] Radical photoinitiator (d) may be chosen from those commonly used to initiate radical photopolymerization. Examples of radical photoinitiators include benzoin, e.g., benzoin, benzoin ethers such as benzoin methyl ether, benzoin ethyl ether, benzoin isopropyl ether, benzoin phenyl ether, and benzoin acetate; acetophenones, e.g., acetophenone, 2,2-dimethoxyacetophenone, and 1,1-



10125508-041002

dichloroacetophenone; benzil ketals, e.g., benzil dimethylketal and benzil diethyl ketal; anthraquinones, e.g., 2-methylantraquinone, 2-ethylantraquinone, 2-tert-butylantraquinone, 1-chloroanthraquinone and 2-amylantraquinone; triphenylphosphine; benzoylphosphine oxides, e.g., 2,4,6-trimethylbenzoyl-diphenylphosphine oxide (Luzirin® TPO); bisacylphosphine oxides; benzophenones, e.g., benzophenone and 4,4'-bis(N,N'-di-methyl-amino)benzophenone; thioxanthenes and xanthenes; acridine derivatives; phenazine derivatives; quinoxaline derivatives; 1-phenyl-1,2-propanedione 2-O-benzoyl oxime; 4-(2-hydroxyethoxy)phenyl-(2-propyl)ketone (Irgacure 2959; Ciba Specialty Chemicals); 1-aminophenyl ketones or 1-hydroxy phenyl ketones, e.g., 1-hydroxycyclohexyl phenyl ketone, 2-hydroxyisopropyl phenyl ketone, phenyl 1-hydroxyisopropyl ketone, and 4-isopropylphenyl 1-hydroxyisopropyl ketone.

[0065] Preferably, the photocurable composition includes a 1-hydroxy phenyl ketone, more preferably 1-hydroxycyclohexyl phenyl ketone, e.g., Irgacure 184 (Ciba Specialty Chemicals).

[0066] The radical photoinitiator is preferably present at from 0.1 to 10 % by weight, more preferably from 0.3 to 8 % by weight, most preferably from 0.4 to 7 % by weight of the photocurable composition.

[0067] Cationic photoinitiators (e) may be chosen from those commonly used to initiate cationic photopolymerization. Examples include onium salts with anions of weak nucleophilicity, e.g., halonium salts, iodosyl salts, sulfonium salts, sulfoxonium salts, or diazonium salts. Metallocene salts are also suitable as photoinitiators. Onium salt and metallocene salt photoinitiators are described in U.S. Patent No. 3,708,296; "UV-Curing, Science and Technology", (Editor: S.P. Pappas, Technology Marketing Corp., Stamford, Connecticut); and "Chemistry & Technology of UV & EB Formulations for Coatings, Inks & Paints," Vol. 3 (edited by P.K.T. Oldring), each of which is incorporated herein by reference.

[0068] Examples of commercial cationic photoinitiators include UVI-6974, UVI-6976, UVI-6970, UVI-6960, UVI-6990 (manufactured by DOW Corp.), CD-1010, CD-1011, CD-1012 (manufactured by Sartomer Corp.), Adekaoptomer SP-150, SP-151, SP-170, SP-171 (manufactured by Asahi Denka Kogyo Co., Ltd.), Irgacure 261 (Ciba Specialty Chemicals Corp.), CI-2481, CI-2624, CI-2639, CI-2064 (Nippon Soda Co, Ltd.), DTS-102, DTS-103, NAT-103, NDS-103, TPS-103, MDS-103, MPI-103, BBI-103 (Midori Chemical Co, Ltd.). Most preferred are UVI-6974, CD-1010, UVI-6976, Adekaoptomer SP-170, SP-171, CD-1012, and MPI-103. The cationic photoinitiators can be used either individually or in combination of two or more. The cationic photoinitiator is preferably present at from 0.05 to 12 % by weight, more preferably from 0.1 to 11 % by weight, most preferably from 0.15 to 10 % by weight of the photocurable composition.

[0069] For stereolithography using a laser, the radical and cationic photoinitiators are preferably selected and their concentrations are preferably adjusted to achieve an absorption capacity such that the depth of cure at the normal laser rate is from about 0.1 to about 2.5 mm.

#### E. Other Components

[0070] The photocurable composition may contain a variety of other components. Examples of such components include modifiers, tougheners, stabilizers, antifoaming agents, leveling agents, thickening agents, flame retardants, antioxidants, pigments, dyes, fillers, and combinations thereof.

[0071] The photocurable composition may contain one or more polytetramethylene ether glycols ("poly THF"). The poly THF preferably has molecular weight from about 250 to 2500. The poly THF may be terminated with hydroxy, epoxy, or ethylenically unsaturated group(s). Polytetramethylene ether glycols are commercially available in the Polymeg® line (Penn Specialty

Chemicals). Preferably, the photocurable composition includes Polymeg® 1000 or Polymeg® 2000.

[0072] The photocurable composition may also contain one or more diols such as 1,4-cyclohexanedimethanol ("CHDM").

[0073] The photocurable composition may also contain one or more stabilizers. Preferred stabilizers are hindered amines, e.g., benzyl dimethyl amine ("BDMA").

#### F. Stereolithography Equipment

[0074] The actinic radiation is generally a beam of light that is controlled by a computer. Preferably, the beam is a laser beam controlled by a mirror.

[0075] In principle any stereolithography machine may be used to carry out the inventive method. Stereolithography equipment is commercially available from various manufacturers. Table I lists commercial SL equipment available from 3D Systems, Inc. (Valencia, CA).

[0076] Table I: Stereolithography Machines

Machine	Wavelength (nm)
SLA 250	325
SLA 2500 (Viper)	355
SLA 3500	355
SLA 500	351
SLA 5000	355
SLA 7000	355

[0077] "Green model" is the 3-D object initially formed by the stereolithography process of layering and curing, where typically the layers are not completely cured. This permits successive layers to better adhere by bonding together when further cured.

[0078] "Postcuring" is the process of reacting a green model to further cure the partially cured layers. A green model may be postcured by exposure to heat, actinic radiation, or both.

[0079] "Green strength" is a general term for mechanical performance properties of a green model, including modulus, strain, strength, hardness, and layer-to-layer adhesion. For example, green strength may be reported by measuring flexural modulus (ASTM D 790). An object having low green strength may deform under its own weight, or may sag or collapse during curing.

[0080] "Penetration depth" ( $D_p$ ) is a property of a given pairing of photocurable composition and laser.  $D_p$  is the slope of a plot ("working curve") of cure depth (mm) against the log of exposure ( $\text{mJ}/\text{cm}^2$ ). "Cure depth" is the measured thickness of a layer formed by exposing the photocurable composition to a specified dose of energy from the laser.

[0081] "Critical Exposure" ( $E_c$ ) is a property of a photocurable composition and expresses the threshold amount of radiation in  $\text{mJ}/\text{cm}^2$  that causes the photocurable composition to gel. The  $E_c$  is the maximum exposure value of the working curve when cure depth is still zero.

[0082] "Dispersed" means a separate phase, e.g., of particles distributed by mixing in a photocurable composition.

## G. EXAMPLES

[0083] The general procedure used for preparing 3-D objects with SL equipment is as follows. The photocurable composition was placed in a 300–700 ml plastic container or in a vat designed for use with the stereolithography machines. The specific container depends on the size of the desired 3-D object. The photocurable composition was poured into the container within the machine at about 30°C. The surface of the composition, in its entirety or a predetermined pattern, was irradiated with a UV/VIS light source so that a layer of a desired

thickness cured and solidified in the irradiated area. A new layer of the photocurable composition was formed on the solidified layer. The new layer was likewise irradiated over the entire surface or in a predetermined pattern. The newly solidified layer adhered to the underlying solidified layer. Repeating the layer formation step and the irradiation step produced a green model of multiple solidified layers.

[0084] The green model was then rinsed in tripropylene glycol monomethyl ether ("TPM"). The green model was then rinsed with water and dried with compressed air. The dried green model was then postcured with UV radiation in a postcure apparatus ("PCA") for about 60 – 90 minutes.

[0085] Stereolithography equipment typically allows for setting various operational parameters. Examples thereof appear in Tables II and III below. The parameters are well known to a person of skill in the art of stereolithography and may be adjusted as needed depending on various factors, including the specific photocurable composition and the geometry of the desired 3-D object.

[0086] "Layer Thickness" is the thickness of each slice or layer of the 3-dimensional object that is to be built.

[0087] "Hatch Overcure" is the depth beyond the layer thickness which is exposed during a given pass (hatch) of the laser.

[0088] "Hatch Spacing" is the distance between adjacent hatch vectors.

[0089] "Fill Cure Depth" is the absolute depth of curing for the fill vectors on a given pass of fill. Fills are tightly spaced vectors drawn on the regions of the part that form upfacing or downfacing surfaces.

[0090] "Fill Spacing" is the distance between adjacent fill vectors.

[0091] "Border Overcure" is the depth beyond the layer thickness that the borders are cured.

[0092] "Preferred Blade Gap" is a distance, given in percent of layer thickness, describing the preferred distance between the bottom of the recoater and last layer of the part at time of sweeping.

[0093] Table II

Parameter	Value
Layer thickness	0.004 inch
Hatch Overcure	0.000 inch
Hatch Spacing	0.004 inch
Fill Cure Depth	0.010 inch
Fill Spacing	0.004 inch
Border Overcure	0.009 inch
Preferred Blade Gap	0.004 inch
D <sub>p</sub>	0.0063 inch
E <sub>c</sub>	9.2 mJ/cm <sup>2</sup>

[0094] Table III

Parameter	Value
Layer thickness	0.006 inch
Hatch Overcure	0.002 inch
Hatch Spacing	0.009 inch
Fill Cure Depth	0.015 inch
Fill Spacing	
Border Overcure	0.012 inch
Preferred Blade Gap	0.004 inch
D <sub>p</sub> (Depth of Penetration)	0.0057 inch
E <sub>c</sub> (Critical Energy)	6.3 mJ/cm <sup>2</sup>

### Example 1

[0095] The following components were mixed at room temperature in a container to form a homogeneous photocurable composition. The composition was an opaque liquid with a viscosity of 195 CPS at 30°C (Brookfield, RVT).

Examples 2-5

[0096] The resin formulations shown in Table IV were prepared using the procedure described for Example 1 (The numbers in Table IV refer to the percent by weight for each component of the total mixture). Table V provides definitions for the trade names in Table IV.

[0097] Table IV

Component	Ex. 1	Ex. 2	Ex. 3	Ex. 4	Ex. 5
Uvacure 1500	49	45.18	39.42	33.95	
Heloxy 48	8	27	28.84	15.52	
Heloxy 84				7.76	10
Heloxy 107	8			12.80	15.1
Gelest DBE-C25			3.85		
Albidur EP 2240	3				
Albidur VB 3320				3	
Albidur EP 5340		10	1.92		40
Dianol 320				7.76	15
Polymeg 1000	6				
Polymeg 2000			7.69		
CHDM	6				
SR 368	10				
SR 399	3	5.4	5.77	5.82	
SR 9041					6.1
Ebecryl 3700		5.67	5.77	6.11	
CN 120					6.3
Vectomer 4010			1.92		
Irgacure 184	2	2.25	1.92	1.94	2.5
UVI 6976	5	4.5	2.88	5.33	5
BDMA	0.01	0.01	0.01	0.010	0.01
Total	100.01	100.01	99.99	100.00	100.01

[0098] Table V: Definitions for Trade Names

Trade Name	Source	Chemical Name
UVACURE 1500	UCB Chemicals Corp. (Radcure)	3,4-Epoxy cyclohexylmethyl 3',4'-epoxycyclohexanecarboxylate
HELOXY 48	Resolution Performance Products LLC	Trimethylolpropane triglycidyl ether
HELOXY 84	Resolution Performance Products LLC	Triglycidyl ether of polypropoxylated glycerol
HELOXY 107	Resolution Performance Products LLC	Diglycidyl ether of CHDM
Gelest DBE-C25	Genesee Polymers Corporation	Poly(dimethylsiloxane), hydroxy(polyethyleneoxy)-propylether terminated
Albidur EP 2240	Hanse Chemie	Silicone-epoxy particles in Bisphenol A epoxy resin
Albidur VE 3320	Hanse Chemie	Silicone-vinyl ester particles in vinyl ester resin and styrene
Albidur EP 5340	Hanse Chemie	Silicone-epoxy particles in alicyclic epoxy resin
Polymeg 1000	Penn Specialty Chemicals	Polytetramethylene ether glycol (MW ca. 1000)
Polymeg 2000	Penn Specialty Chemicals	Polytetramethylene ether glycol (MW ca. 2000)
CHDM 99%	Aldrich Chemical Co.	1,4-Cyclohexanedimethanol
Dianol 320	Seppic, Inc.	Dipropoxylated bisphenol A
SR 368	Sartomer Co.	Tris(2-hydroxy ethyl) isocyanurate triacrylate
SR 399	Sartomer Co.	Dipentaerythritol pentaacrylate
SR 9041	Sartomer Co.	Pentaacrylate ester
CN 120	Sartomer Co.	Bisphenol A Epoxy Diacrylate
Ebecryl 3700	Radcure Specialties	Bisphenol A diglycidyl ether diacrylate [4687-94-9]
Vectomer 4010	Morflex, Inc.	Bis[4-(vinyl oxy)butyl] isophthalate, 98%
Irgacure 184	Ciba Specialty Chemicals	1-hydroxycyclohexyl phenyl ketone
Cyracure UVI 6976	Dow Chemical Company	Mixture of $\text{PhS}-(\text{C}_6\text{H}_4)-\text{S}^+\text{Ph}_2\text{SbF}_6^-$ and $\text{Ph}_2\text{S}^+-(\text{C}_6\text{H}_4)\text{S}(\text{C}_6\text{H}_4)-\text{S}^+\text{Ph}_2(\text{SbF}_6^-)_2$

**Example 9**

[0099] A 3D Systems Viper Si2 (SLA 2500) machine was used to prepare 10 objects using the formulation of Example 1. The machine settings used are those in Table II. The objects were opaque white or off-white and had a glossy surface.



Example 10

[00100] An SLA 5000 machine was used to prepare 24 objects using the formulation of Example 1. The machine settings used are those in Table III. The objects were opaque white or off-white and had a glossy surface.

[00101] While embodiments of the invention have been described above, those embodiments illustrate but do not limit the invention. Adaptations and variations of those embodiments are within the scope of the invention as set forth in the following claims.

1042508-041902  
2006-10-28 05:52:10

WE CLAIM:

1. A photocurable composition, comprising:
  - (a) a cationically curable monomer;
  - (b) a radically curable monomer;
  - (c) reactive particles comprising a crosslinked polysiloxane core and a shell of reactive groups on an outer surface of the core, wherein the reactive groups comprise epoxy groups, ethylenically unsaturated groups, or hydroxy groups;
  - (d) a radical photoinitiator; and
  - (e) a cationic photoinitiator.
2. A composition as claimed in claim 1, wherein the core comprises dialkylsiloxane repeating units.
3. A composition as claimed in claim 2, wherein the core comprises dimethylsiloxane repeating units.
4. A composition as claimed in claim 1, wherein the reactive groups comprise epoxy groups.
5. A composition as claimed in claim 4, wherein the reactive particles comprise Albidur EP 2240 or Albidur EP 5340.
6. A composition as claimed in claim 1, wherein the reactive groups comprise ethylenically unsaturated groups.
7. A composition as claimed in claim 6, wherein the reactive particles comprise VE 3320.

8. A composition as claimed in claim 1, wherein the reactive particles have an average particle diameter of from 0.01 and 50  $\mu\text{m}$ .

9. A composition as claimed in claim 1, wherein the reactive particles are capable of reacting substantially completely to form chemical bonds to a polymer matrix that is formed on curing the photocurable composition.

10. A composition as claimed in claim 1, wherein (a) comprises a polyepoxide.

11. A composition as claimed in claim 10, wherein (a) comprises an alicyclic polyepoxide.

12. A composition as claimed in claim 11, wherein the alicyclic polyepoxide has monomer purity of over about 94 %.

13. A composition as claimed in claim 1, wherein (b) comprises a poly(meth)acrylate.

14. A composition as claimed in claim 13, comprising a poly(meth)acrylate having a hydroxy group.

15. A composition as claimed in claim 13, wherein (b) comprises a di(meth)acrylate and a poly(meth)acrylate containing at least three (meth)acrylate groups.

16. A composition as claimed in claim 1, further comprising a polyether polyol.

17. A method comprising:

- (1) forming a first layer of the photocurable composition of claim 1;
- (2) exposing the first layer to actinic radiation sufficient to harden the first layer;
- (3) forming a second layer of the photocurable composition of claim 1 above the hardened first layer;
- (4) exposing the second layer to actinic radiation sufficient to harden the second layer; and
- (5) repeating steps (3) – (4) as needed to form a 3-D object.

18. A method as claimed in claim 17, further comprising a step of postcuring the 3-D object.

19. A 3-D object, prepared by the method of claim 17.

20. The 3-D object of claim 19, wherein the 3-D object is opaque.

**ABSTRACT OF THE DISCLOSURE**

A photocurable composition, including (a) a cationically curable monomer; (b) a radically curable monomer; (c) reactive particles comprising a crosslinked polysiloxane core and a shell of reactive groups on an outer surface of the core, wherein the reactive groups comprise epoxy groups, ethylenically unsaturated groups, or hydroxy groups; (d) a radical photoinitiator; and (e) a cationic photoinitiator. A method of making a 3-D object from such a composition. A 3-D object made by the method.

200710-041902

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION</b> <b>(37 CFR 1.63)</b>  <input checked="" type="checkbox"/> Declaration Submitted with Initial Filing      OR <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.18 (e)) required)	Attorney Docket Number	272/142
	First Named Inventor	John W. Fong
	<b>COMPLETE IF KNOWN</b>	
	Application Number	/
	Filing Date	
	Art Unit	
	Examiner Name	

As the below named inventor, I hereby declare that:  
 My residence, mailing address, and citizenship are as stated below next to my name.  
 I believe I am the original and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**Photocurable Compositions Containing Reactive Polysiloxane Particles**

(Title of the invention)

the specification of which

☒ is attached hereto

OR

☐ was filed on (MM/DD/YYYY)

as United States Application Number or PCT International

Application Number

and was amended on (MM/DD/YYYY)

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 385(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## DECLARATION — Utility or Design Patent Application

Direct all correspondence to: <input checked="" type="checkbox"/>		Customer Number or Bar Code Label	22249	OR <input type="checkbox"/>	Correspondence address below
Name					
Address					
City		State		ZIP	
Country		Telephone		Fax	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.					
NAME OF SOLE OR FIRST INVENTOR: <input type="checkbox"/>				A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		John W.		Family Name or Surname Fong	
Inventor's Signature		John W. Fong		Date 4/19/2002	
Residence: City		Temple city		State CA	
Country		U.S.A.		Citizenship U.S.A.	
Mailing Address 5121 San Fernando Road West.					
City		Los Angeles		State CA	
ZIP		90039		Country U.S.A.	
NAME OF SECOND INVENTOR: <input type="checkbox"/>				A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		David L.		Family Name or Surname Johnson	
Inventor's Signature		David L. Johnson		Date 4/19/2002	
Residence: City		Saugus		State CA	
Country		USA		Citizenship USA	
Mailing Address 5121 San Fernando Road West					
City		Los Angeles		State CA	
ZIP		90039		Country USA	
<input type="checkbox"/> Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.					

[Page 2 of 2]

Please type a plus sign (+) inside this box → ☐

PTO/SB/81 (02-01)

Approved for use through 10/31/2002. OMB 0551-0035

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY OR  
AUTHORIZATION OF AGENT**

Application Number	
Filing Date	
First Named Inventor	John W. Fong
Title	PHOTOCURABLE COMPOSITIONS CONTAINING REACTIVE POLYSILOXANE PARTICLES
Group Art Unit	
Examiner Name	
Attorney Docket Number	272/142

I hereby appoint:

☒ Practitioners at Customer Number  
OR

22249

Place Customer  
Number Bar Code  
Label here

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for this above identified application to:

☐ The above mentioned Customer Number.

OR

☐ Practitioners at Customer Number

Place Customer  
Number Bar Code  
Label here

☐ Firm or  
Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

**SIGNATURE of Applicant or Assignee of Record**

Name	David L. Johnson
Signature	<i>David L. Johnson</i>
Date	April 19, 2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of 2 forms are submitted.

Burdan Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box 

PTD/ARJ1 (02-01)

Approved for use through 10/31/2002. OMB 0861-0098

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>POWER OF ATTORNEY FOR AUTHORIZATION OF AGENT</b>	Application Number	4
	Full Name	
	Home Address	
	City	
	State	
	Country	

**I hereby appoint**

☒. Predictions at Customer Number

**OR**

☐ Practitioner(s) named below:

**Place Customer  
Number Bar Code  
Label here**

[illegible]

as my/our attorney(s) or agent(s) to prosecute the application, defend the same, and to transact all business in the United States Patent and Trademark Office on behalf of the said.

**Please change the correspondence address for the above-identified application to:**

☐ The above-mentioned Customer Number.

**OR**

### ☐ Practitioners at Customer Number

**GA**

Place Customer  
Number on Code  
Label here

☐ Firm or  
Individual Name

**Address**

**Address**

Give

**Country:**

**COUNTRY**  
Thailand

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

**ខែ ឆ្នាំ ថ្ងៃ:**

☒ **Applicant/Inventor.**

☐ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 2.73(b) is enclosed. (Form FPLS 98)

SIGNATURE of Applicant or Assignee of Record

**Nabur**

**John W. Bong**

**Signature**

Ann. W. 1. Fm.

**Daler**

April 19 2002

NOTE: Signatures of all the persons exercising the right of the entire interest or (if expressible) are required. Submit multiple copies if more than one signatory is required, as below.

27 Total of 3 . . . . .

**Burden Hour Statement:** This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the time burden of this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**